MetaVia initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of MetaVia (MTVA) with a Buy rating and $12 price target The company’s DA-1726 is a novel oxyntomodulin analogue designed as a dual agonist targeting glucagon-like peptide-1 and glucagon receptors, the analyst tells investors in a research note. The firm is “intrigued” by DA-1726’s effects among dual GLP-1 agonists. It views the 5.8% placebo-adjusted mean weight loss at week six from a Phase 1 study of survodutide as an approximate early benchmark for DA-1726. It views view DA-1241 as MetaVia’s “wild card” to the metabolic dysfunction-associated steatohepatitis market.